Abstract
Background
Metabolic syndrome (MetS) is a risk factor for diabetes, cardiovascular disease, and heart failure, but little is known about the impact of MetS in patients who already have heart failure (HF).
Hypothesis
MetS increases mortality in HF.
Methods
We performed an analysis in 865 indigent HF patients enrolled in a HF disease management program at the Chabert Medical Center in Louisiana. All subjects were classified as having MetS if they met three or more of the National Cholesterol Education Program criteria. Mortality was defined using the Social Security Death Index. We calculated the relative hazard (RH) of death for those patients with and without MetS.
Results
The prevalence of MetS was 40% (95% confidence interval [CI]: 37–43). These subjects had similar ages (54.3±13.4 vs 55.7±12.8 years), more likely to be female (43% vs 33%), had similar baseline ejection fraction (31.4±9.7 vs 30.0±11.0), and New York Heart Association (NYHA) classification (2.20±0.9 vs 2.15±0.9). After 2.6±2.2 years of follow‐up 24% of the MetS group died compared to 16% in the non‐MetS group (p < 0.01). The RH of death for the MetS group was 1.5 (95% CI: 1.1–2.1) when compared to the non‐MetS group after adjustment demographics, use of angiotensin‐converting enzyme (ACE) inhibitor and β‐blocker, hematocrit, creatinine, educational level, and baseline ejection fraction.
Conclusions
The prevalence of MetS is high in indigent HF patients, and it increases the risk of death. Physicians treating patients with HF need to address the current MetS epidemic in HF. Copyright © 2009 Wiley Periodicals, Inc.
Full Text
The Full Text of this article is available as a PDF (785.3 KB).
References
- 1. Ford ES. Risks for all‐cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778. [DOI] [PubMed] [Google Scholar]
- 2. Gami AS, Witt BJ, Howard DE, et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta‐analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–414. [DOI] [PubMed] [Google Scholar]
- 3. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28: 2745–2749. [DOI] [PubMed] [Google Scholar]
- 4. Hu G, Qiao Q, Tuomilehto J, et al. Prevalence of the metabolic syndrome and its relation to all‐cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–1076. [DOI] [PubMed] [Google Scholar]
- 5. Lorenzo C, Williams K, Gonzalez‐Villalpando C, Haffner SM. The prevalence of the metabolic syndrome did not increase in Mexico City between 1990–1992 and 1997–1999 despite more central obesity. Diabetes Care 2005; 28: 2480–2485. [DOI] [PubMed] [Google Scholar]
- 6. Kannel WB. Incidence and epidemiology of heart failure. Heart Fail Rev 2000; 5: 167–173. [DOI] [PubMed] [Google Scholar]
- 7. Ingelsson E, Arnlov J, Lind L, Sundstrom JMc. Metabolic syndrome and risk for heart failure in middle‐aged men. Heart 2006; 92: 1409–1413. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Wong CY, O'Moore‐Sullivan T, Fang ZY, et al. Myocardial and vascular dysfunction and exercise capacity in the metabolic syndrome. Am J Cardiol 2005; 96: 1686–1691. [DOI] [PubMed] [Google Scholar]
- 9. Azevedo A, Bettencourt P, Almeida PB, et al. Increasing number of components of the metabolic syndrome and cardiac structural and functional abnormalities—cross‐sectional study of the general population. BMC Cardiovasc Disord 2007; 7: 17. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Burchfiel CM, Skelton TN, Andrew ME, et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005; 112: 819–827. [DOI] [PubMed] [Google Scholar]
- 11. Echahidi N, Pibarot P, Despres JP, et al. Metabolic syndrome increases operative mortality in patients undergoing coronary artery bypass grafting surgery. J Am Coll Cardiol 2007; 50: 843–851. [DOI] [PubMed] [Google Scholar]
- 12. Feinberg MS, Schwartz R, Tanne D, et al. Impact of the metabolic syndrome on the clinical outcomes of non‐clinically diagnosed diabetic patients with acute coronary syndrome. Am J Cardiol 2007; 99: 667–672. [DOI] [PubMed] [Google Scholar]
- 13. Levantesi G, Macchia A, Marfisi R, et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277–283. [DOI] [PubMed] [Google Scholar]
- 14. Zeller M, Steg PG, Ravisy J, et al. Prevalence and impact of metabolic syndrome on hospital outcomes in acute myocardial infarction. Arch Intern Med 2005; 165: 1192–1198. [DOI] [PubMed] [Google Scholar]
- 15. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497. [DOI] [PubMed] [Google Scholar]
- 16. Pyorala K, Ballantyne CM, Gumbiner B, et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 2004; 27: 1735–1740. [DOI] [PubMed] [Google Scholar]
- 17. Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136–141. [DOI] [PubMed] [Google Scholar]
- 18. He Y, Jiang B, Wang J, et al. Prevalence of the metabolic syndrome and its relation to cardiovascular disease in an elderly Chinese population. J Am Coll Cardiol 2006; 47: 1588–1594. [DOI] [PubMed] [Google Scholar]
- 19. Otiniano ME, Du XL, Maldonado MR, Ray L, Markides K. Effect of metabolic syndrome on heart attack and mortality in Mexican‐American elderly persons: findings of 7‐year follow‐up from the Hispanic established population for the epidemiological study of the elderly. J Gerontol A Biol Sci Med Sci 2005; 60: 466–470. [DOI] [PubMed] [Google Scholar]
- 20. Malik S, Wong ND, Franklin SS, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245–1250. [DOI] [PubMed] [Google Scholar]
- 21. de Simone G, Devereux RB, Chinali M, et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: The Strong Heart Study. Diabetes Care 2007; 30: 1851–1856. [DOI] [PubMed] [Google Scholar]
- 22. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle‐aged men. JAMA 2002; 288: 2709–2716. [DOI] [PubMed] [Google Scholar]
- 23. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990; 82: 1724–1729. [DOI] [PubMed] [Google Scholar]
- 24. Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995; 92: 3206–3211. [DOI] [PubMed] [Google Scholar]
- 25. Hasking GJ, Esler MD, Jennings GL, et al. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation 1986; 73 615–621. [DOI] [PubMed] [Google Scholar]
- 26. Grassi G, Dell'Oro R, Quarti‐Trevano F, et al. Neuroadrenergic and reflex abnormalities in patients with metabolic syndrome. Diabetologia 2005; 48: 1359–1365. [DOI] [PubMed] [Google Scholar]
- 27. Huggett RJ, Burns J, Mackintosh AF, Mary DA. Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension. Hypertension 2004; 44: 847–852. [DOI] [PubMed] [Google Scholar]
- 28. Grassi G, Seravalle G, Quarti‐Trevano F, Scopelliti F, Dell'Oro R, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: Characteristics and mechanisms. Hypertension 2007; 49: 535–541. [DOI] [PubMed] [Google Scholar]